ATE258068T1 - Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe - Google Patents

Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe

Info

Publication number
ATE258068T1
ATE258068T1 AT95941351T AT95941351T ATE258068T1 AT E258068 T1 ATE258068 T1 AT E258068T1 AT 95941351 T AT95941351 T AT 95941351T AT 95941351 T AT95941351 T AT 95941351T AT E258068 T1 ATE258068 T1 AT E258068T1
Authority
AT
Austria
Prior art keywords
composition
improved electrical
active delivery
electrical transport
transport active
Prior art date
Application number
AT95941351T
Other languages
English (en)
Inventor
J Richard Gyory
Jane Yieh
James A Huntington
Michel Cormier
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ATE258068T1 publication Critical patent/ATE258068T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
AT95941351T 1994-11-14 1995-11-01 Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe ATE258068T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/339,092 US5861439A (en) 1994-11-14 1994-11-14 Method for enhanced electrotransport agent delivery
PCT/US1995/014175 WO1996014870A1 (en) 1994-11-14 1995-11-01 Composition, device, and method for enhanced electrotransport agent delivery

Publications (1)

Publication Number Publication Date
ATE258068T1 true ATE258068T1 (de) 2004-02-15

Family

ID=23327470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95941351T ATE258068T1 (de) 1994-11-14 1995-11-01 Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe

Country Status (8)

Country Link
US (3) US5861439A (de)
EP (1) EP0792164B1 (de)
JP (1) JP3950169B2 (de)
AT (1) ATE258068T1 (de)
CA (1) CA2202137C (de)
DE (1) DE69532477T2 (de)
ES (1) ES2214513T3 (de)
WO (1) WO1996014870A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
US6757560B1 (en) * 1999-04-09 2004-06-29 Novosis Pharma Ag Transdermal delivery system (TDS) with electrode network
US6647111B1 (en) * 1998-05-07 2003-11-11 Mci Communications Corporation System for executing advanced interactive voice response services using service-independent building blocks
EP1229922B1 (de) * 1999-11-15 2007-06-06 Pharma Mar, S.A. Behandlung von krebserkrankungen durch aplidin
UA76718C2 (uk) * 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
GB0017999D0 (en) 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
KR20030038812A (ko) * 2000-10-12 2003-05-16 파르마 마르, 에스.에이. 암 치료 방법
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
DE10122324A1 (de) * 2001-05-08 2002-11-14 Philips Corp Intellectual Pty Flexible integrierte monolithische Schaltung
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE60229414D1 (de) * 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
AU2002251541A1 (en) * 2002-04-25 2003-11-10 Centre Pharmapeptides Apparatus and assembly for administering antimicrobial agent
AU2003282683A1 (en) * 2002-10-04 2004-05-04 Photokinetix Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
NZ541611A (en) * 2003-03-12 2008-04-30 Dana Farber Cancer Inst Inc Aplidine for multiple myeloma treatment
US7706873B2 (en) * 2004-05-05 2010-04-27 Mario Ammirati System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue
WO2007139826A2 (en) * 2006-05-26 2007-12-06 Cara Therapeutics, Inc. Method for elevating prolactin in mammals
US20090137925A1 (en) * 2007-11-23 2009-05-28 Divya Cantor Impedance Spectroscopy Cervix Scanning Apparatus and Method

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
CA1165240A (en) * 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
JPS5855411A (ja) * 1981-09-28 1983-04-01 Nitto Electric Ind Co Ltd 基剤組成物および外用医薬組成物
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4615699A (en) * 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
US4692328A (en) * 1985-09-24 1987-09-08 Dynatech Corporation Biologically useful polymer preparations
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
ATE77559T1 (de) * 1986-11-14 1992-07-15 Theratech Inc Erhoehung des penetrationsvermoegens mittels eines aus die zellhuelle veraendernden substanzen und kurzkettigen alkoholen bestehenden binaeren systems.
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
JPS6425717A (en) * 1987-05-08 1989-01-27 Eastman Kodak Co Method and apparatus for preventing organic nitric acid ester resistance
DE3819842C1 (de) * 1988-03-23 1989-12-21 Karl Heinz Dr. 7100 Heilbronn De Thiel
US5162042A (en) * 1988-07-05 1992-11-10 Alza Corporation Electrotransport transdermal system
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US5147296A (en) * 1988-10-03 1992-09-15 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5169382A (en) * 1988-10-03 1992-12-08 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5234992A (en) * 1989-02-09 1993-08-10 Alza Corporation Electrotransport adhesive
US5240995A (en) * 1989-02-09 1993-08-31 Alza Corporation Electrotransport adhesive
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5125894A (en) * 1990-03-30 1992-06-30 Alza Corporation Method and apparatus for controlled environment electrotransport
US5149719A (en) * 1990-04-27 1992-09-22 Minnesota Mining And Manufacturing Company Composition for transdermal penetration of medicaments
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5356632A (en) * 1991-09-12 1994-10-18 S.I. Scientific Innovations Ltd. Transdermal drug delivery device
US5312439A (en) * 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
ATE169826T1 (de) * 1992-01-21 1998-09-15 Macrochem Corp Iontophoretische verbesserte verabreichung von medikamenten
US5240495A (en) * 1992-04-02 1993-08-31 Cornell Research Foundation, Inc. In situ formation of metal-ceramic oxide microstructures
US5380271A (en) * 1992-09-24 1995-01-10 Alza Corporation Electrotransport agent delivery device and method
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery

Also Published As

Publication number Publication date
WO1996014870A1 (en) 1996-05-23
ES2214513T3 (es) 2004-09-16
CA2202137C (en) 2008-02-12
US5883135A (en) 1999-03-16
CA2202137A1 (en) 1996-05-23
EP0792164A1 (de) 1997-09-03
US6083190A (en) 2000-07-04
DE69532477T2 (de) 2004-11-25
DE69532477D1 (de) 2004-02-26
JP3950169B2 (ja) 2007-07-25
JPH10508850A (ja) 1998-09-02
US5861439A (en) 1999-01-19
EP0792164B1 (de) 2004-01-21

Similar Documents

Publication Publication Date Title
ATE258068T1 (de) Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe
DE69011878D1 (de) Von Hydrogel angetriebene Verabreichungsvorrichtung.
ATE369150T1 (de) Zusammensetzungen, vorrichtung und verfahren zur elektrotransport-wirkstoffabgabe
DE69130232D1 (de) Transdermale verhütungsmittelformulierung, verfahren und vorrichtung
ATE277671T1 (de) Vorrichtung zur verbesserung der transdermalen abnahme von körperflüssigkeiten
DE58904704D1 (de) Verfahren und vorrichtung zur oberflaechenvorbehandlung von ein- oder mehrschichtigem formmaterial mittels einer elektrischen koronaentladung.
ATA88084A (de) Vorrichtung zur kontrollierten abgabe eines wirkstoffes
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
AU7323794A (en) Method and device for providing nicotine replacement therapy transdermally/transbuccally
DE69519393D1 (de) Zusammensetzung und verfahren zur förderung von transdermaler elektrotransport-darreichung
IT1289728B1 (it) Dispositivo di impianto e corredo che lo comprende
EP0384266A3 (en) Therapeutic system for the sustained and controlled transdermal or transmucosal delivery of active agents
DE69623608D1 (de) Zusammensetzung zur verbesserten elektroübertragunslieferung von wirkstoff
DE59503114D1 (de) Vorrichtung zur Abgabe von Auftrags-Material
DE69315272D1 (de) Verfahren zur Strahlregulierung und Gerät zur Behandlung von Schädigungen mittels hoch-energetische Bestrahlungen
DE68917550D1 (de) Verfahren und Vorrichtung zur Plasmabehandlung.
ATE247504T1 (de) Vorrichtung zur behandlung des menschlichen körpers durch endermatische elektrotherapie
DE69328256D1 (de) Vorrichtung zur implantierung von defibrillations-elektroden
DE69115150D1 (de) Verfahren und Gerät zur Bestrahlung mittels niederenergetischer Elektronen.
DE69613370D1 (de) Zusammensetzung und verfahren zur verstärkung von elektrotransport-wirkstoffzufuhr
DE69108166D1 (de) Verfahren und Vorrichtung zur Regelung eines Wechselstromgenerators.
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
ATE20313T1 (de) Elektrotherapeutische vorrichtung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties